<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Marketing Inc.</title>
	<atom:link href="http://www.stockmarketinginc.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.stockmarketinginc.com</link>
	<description>who said YOUR money can&#039;t grow?</description>
	<lastBuildDate>Mon, 23 Aug 2010 16:44:38 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<item>
		<title></title>
		<link>http://www.stockmarketinginc.com/2010/08/20/1876/</link>
		<comments>http://www.stockmarketinginc.com/2010/08/20/1876/#comments</comments>
		<pubDate>Fri, 20 Aug 2010 12:56:10 +0000</pubDate>
		<dc:creator>Stock Marketing, Inc.</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.stockmarketinginc.com/?p=1876</guid>
		<description><![CDATA[CHTP Chelsea Therapeutics International, Ltd. LChelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea&#8217;s most advanced drug candidate, Northera(TM) (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to [...]]]></description>
			<content:encoded><![CDATA[<p style="text-align: center;"><span style="color: #008000;"><strong><span style="font-family: 'arial black','avant garde'; color: #4f604f;"><span style="font-size: large;"><span style="font-family: Verdana,Geneva,Arial,Helvetica,sans-serif; color: #4f604f; font-size: xx-small;"><span style="font-family: arial black,avant garde; font-size: x-large;">CHTP</span><span style="font-family: arial black,avant garde;"><span style="font-size: xx-small;"> </span></span></span><span style="font-family: arial,helvetica,sans-serif;"><span style="font-size: x-small;"><span style="color: #000000;"><br />
</span></span></span></span></span></strong></span><span style="font-size: medium;"><strong><span style="font-family: arial,helvetica,sans-serif;">Chelsea Therapeutics International, Ltd.</span></strong></span><br />
<span style="color: #008000;"><strong><span style="font-family: 'arial black','avant garde'; color: #4f604f;"><span style="font-size: large;"><span style="font-family: arial,helvetica,sans-serif;"><span style="font-size: x-small;"><span style="color: #000000;"><br />
</span></span></span><span style="font-family: arial, helvetica, sans-serif; color: #008000;"><span style="font-size: small;"><a href="http://www.stockmarketinginc.com/wp-content/uploads/2010/08/Screen-shot-2010-08-23-at-12.29.26-PM.png"><img class="aligncenter size-full wp-image-1891" title="Screen shot 2010-08-23 at 12.29.26 PM" src="http://www.stockmarketinginc.com/wp-content/uploads/2010/08/Screen-shot-2010-08-23-at-12.29.26-PM.png" alt="" width="296" height="50" /></a><br />
</span></span></span></span></strong></span></p>
<p style="text-align: center;"><span style="font-size: medium;">LChelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. </span></p>
<p style="text-align: center;"><span style="font-size: medium;">Chelsea&#8217;s most advanced drug candidate, Northera(TM) (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. </span></p>
<p style="text-align: center;"><span style="font-size: medium;">In addition to Northera, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. </span></p>
<p style="text-align: center;"><span style="font-size: medium;">Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).</span></p>
<p style="text-align: center;"><span style="font-size: large;"><span style="color: #008000;"><span style="font-family: 'arial black', 'avant garde';">WEBSITE</span></span></span></p>
<div style="text-align: center;"><span style="font-size: small;"><strong><span style="font-size: medium;"><a href="http://www.chelseatherapeutics.com/" target="_blank"><span style="color: #0000ff;"><span style="font-family: arial, helvetica, sans-serif;">http://www.chelseatherapeutics.com/</span></span></a></span></strong></span></div>
<div style="text-align: center;"><span style="font-size: small;"><strong><span style="font-size: medium;"><span style="font-family: arial, helvetica, sans-serif;"><br />
</span></span></strong></span></div>
<p style="text-align: center;"><span style="font-size: small;"><span style="font-size: small;"><span style="font-size: large;"><span style="font-size: x-large;"><span style="font-size: large;"><span style="color: #008000;"><span style="font-family: 'arial black', 'avant garde';">LATEST NEWS</span></span></span></span></span></span></span></p>
<p style="text-align: center;"><span style="font-size: small;"><span style="font-size: medium;"><span style="font-family: arial, helvetica, sans-serif;"><strong><a href="http://finance.yahoo.com/news/Chelsea-Therapeutics-pz-3456024445.html?x=0&amp;.v=1" target="_blank"><span style="color: #0000ff;"><span style="font-family: arial, helvetica, sans-serif;">Chelsea Therapeutics Announces Initiation of Investigator-Led Phase II Study of Droxidopa in Chronic Fatigue Syndrome</span></span></a></strong></span></span></span></p>
<p style="text-align: center;"><span style="color: #008000;"><strong><span style="font-family: 'arial black','avant garde'; color: #4f604f;"><span style="font-size: large;"><a href="http://finance.yahoo.com/q?s=CHTP" target="_blank"><span style="font-family: Verdana,Geneva,Arial,Helvetica,sans-serif; color: #4f604f; font-size: xx-small;"><span style="font-family: arial black,avant garde; font-size: x-large;"><span style="font-size: large;"><span style="color: #008000;"><span style="font-family: 'arial black', 'avant garde';">FINANCE &amp; NEWS</span></span></span></span></span></a></span></span><span style="font-family: 'arial black','avant garde'; color: #4f604f;"><span style="font-size: large;"><a href="http://blast.newslettersignup.net/link.php?M=75990&amp;N=589&amp;L=437&amp;F=H" target="_blank"><span style="font-family: Verdana,Geneva,Arial,Helvetica,sans-serif; color: #4f604f; font-size: xx-small;"><span style="font-family: arial black,avant garde; font-size: x-large;"><span style="font-size: large;"><br />
</span></span></span></a></span></span></strong></span><span style="color: #008000;"><strong> </strong></span><span style="color: #008000;"><strong> </strong></span><strong><br />
</strong></p>
]]></content:encoded>
			<wfw:commentRss>http://www.stockmarketinginc.com/2010/08/20/1876/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
